ArticleBriefings in bioinformatics2026
From early-onset asthma to chronic obstructive pulmonary disease: potential mediating proteins and therapeutic targets.
Article in Briefings in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
BACKGROUND AND
objectiveEarly-onset asthma (EOA) significantly increases the risk of chronic obstructive pulmonary disease (COPD), yet the causal mechanisms and molecular mediators underlying this progression remain poorly understood. Multi-omics integration provides a powerful framework for prioritizing potential mediating proteins and disease-specific therapeutic candidates.
methodsThis study integrated large-scale genetic and proteomic data using Mendelian randomization (MR) approaches to investigate the progression from EOA to COPD. Proteome-wide MR evaluated protein quantitative trait loci (pQTLs) in relation to EOA and COPD risk, with mediation analysis evaluating their roles and single-cell transcriptomics defining the cell-type-specific expression of the mediating proteins. Finally, colocalization, multi-tissue expression quantitative trait loci (eQTLs), and druggability assessment were used to prioritize potential disease-specific therapeutic targets.
resultsEvidence from genetic instruments supports a causal relationship between EOA and COPD. Proteome-wide analyses of 7847 pQTLs identified 339 proteins with potential effects on EOA and 389 on COPD. Six proteins, KREMEN1, BLMH, CNTN5, IL1RN, MIA, and PILRA, showed statistically significant mediation effects in the EOA-to-COPD pathway. PILRA strongly colocalized at shared genetic loci between the two diseases and was significantly downregulated in macrophages from COPD patients. For disease-specific targets, immune-tissue eQTL validation supported ITPKA in EOA. Integration of druggability assessment with multi-tissue eQTL analyses prioritized FES, CCN3, NMI, and NMT1 as promising therapeutic candidates for COPD.
conclusionThese findings provide genetic evidence supporting a causal relationship between EOA and COPD, reveal putative mediating proteins, and prioritize therapeutic candidates with translational potential, offering new insights into pathogenesis, prevention, and intervention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.